Communiqués AN2 Therapeutics, Inc.

Actions

ANTX

US0373261058

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:36:31 15/09/2026			Varia. 5j.	Varia. 1 janv.
5,295 ^USD	-3,02%		-11,79%	+362,72%

24/08	AN2 Therapeutics, Inc. annonce la nomination du Dr Cameron Trenor au poste de directeur médical	CI
11/08	AN2 Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

01/09	AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting	BU
24/08	AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer	BU
11/08	AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights	BU
04/06	AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease	BU
21/05	AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference	BU
11/05	AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights	BU
07/05	AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum	BU
31/03	AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease	BU
17/03	AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights	BU
09/03	AN2 Therapeutics Announces $40 Million Private Placement Financing	BU
03/03	AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)	BU
17/02	AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference	BU
04/02	AN2 Therapeutics : Initial Statement of Beneficial Ownership (Form 3)	PU
12/01	AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease	BU
12/11	AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights	BU
10/11	AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)	BU
06/11	AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference	BU
12/08/25	AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights	BU
12/08/25	AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease	BU
23/07/25	AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease	BU
30/06/25	AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole	BU
29/05/25	AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference	BU
13/05/25	AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights	BU
01/05/25	AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline	BU
30/04/25	AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference	BU